We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
Read MoreHide Full Article
Small biotech Aprea Therapeutics, Inc. (APRE - Free Report) announced that the FDA has removed the full clinical hold on a study evaluating its lead product candidate, eprenetapopt (APR-246), in combination with other cancer drugs for treating lymphoid malignancies.
The study is investigating eprenetapopt in combination with AstraZeneca’s (AZN - Free Report) Calquence (acalabrutinib), or with AbbVie (ABBV - Free Report) /Roche’s Venclexta (venetoclax) and Roche’s (RHHBY - Free Report) Rituxan (rituximab) for the given indication.
Aprea Therapeutics addressed the FDA’s concern and received clearance from the regulatory body to resume clinical evaluation of eprenetapopt in non-Hodgkin’s lymphomas.
Venclexta has been developed by AbbVie and Roche. The drug is being jointly commercialized by AbbVie and Roche in the United States while AbbVie markets the drug in ex-U.S. markets under the brand name Venclyxto.
AstraZeneca’s Calquence is approved for chronic lymphocytic leukemia (in frontline as well as relapsed/recurrent disease setting) and previously treated mantle cell lymphoma.
Shares of Aprea Therapeutics were up 2.2% on Thursday following the FDA’s removal of clinical hold on the above-mentioned study on eprenetapopt. The stock has plunged 14.4% so far this year compared with the industry’s decrease of 19.6%.
Image Source: Zacks Investment Research
Aprea Therapeutics is developing eprenetapopt for treating hematologic malignancies and solid tumors.
Please note that in August 2021, the FDA placed a clinical hold on the lymphoid malignancy program owing to concerns over the safety and efficacy data from the phase III frontline study in myelodysplastic syndromes (“MDS”).
The same month, the FDA placed a partial clinical hold on several studies evaluating eprenetapopt in combination with Vidaza (azacitidine), including a phase III frontline MDS. All these studies were put on clinical hold due to concerns about the safety and efficacy data from the frontline MDS study.
The FDA has granted Orphan Drug and Fast Track designations to eprenetapopt for treating MDS as well as acute myeloid leukemia (“AML”). The European Commission has also granted Orphan Drug designation to eprenetapopt for MDS and AML.
Image: Shutterstock
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
Small biotech Aprea Therapeutics, Inc. (APRE - Free Report) announced that the FDA has removed the full clinical hold on a study evaluating its lead product candidate, eprenetapopt (APR-246), in combination with other cancer drugs for treating lymphoid malignancies.
The study is investigating eprenetapopt in combination with AstraZeneca’s (AZN - Free Report) Calquence (acalabrutinib), or with AbbVie (ABBV - Free Report) /Roche’s Venclexta (venetoclax) and Roche’s (RHHBY - Free Report) Rituxan (rituximab) for the given indication.
Aprea Therapeutics addressed the FDA’s concern and received clearance from the regulatory body to resume clinical evaluation of eprenetapopt in non-Hodgkin’s lymphomas.
Venclexta has been developed by AbbVie and Roche. The drug is being jointly commercialized by AbbVie and Roche in the United States while AbbVie markets the drug in ex-U.S. markets under the brand name Venclyxto.
AstraZeneca’s Calquence is approved for chronic lymphocytic leukemia (in frontline as well as relapsed/recurrent disease setting) and previously treated mantle cell lymphoma.
Shares of Aprea Therapeutics were up 2.2% on Thursday following the FDA’s removal of clinical hold on the above-mentioned study on eprenetapopt. The stock has plunged 14.4% so far this year compared with the industry’s decrease of 19.6%.
Image Source: Zacks Investment Research
Aprea Therapeutics is developing eprenetapopt for treating hematologic malignancies and solid tumors.
Please note that in August 2021, the FDA placed a clinical hold on the lymphoid malignancy program owing to concerns over the safety and efficacy data from the phase III frontline study in myelodysplastic syndromes (“MDS”).
The same month, the FDA placed a partial clinical hold on several studies evaluating eprenetapopt in combination with Vidaza (azacitidine), including a phase III frontline MDS. All these studies were put on clinical hold due to concerns about the safety and efficacy data from the frontline MDS study.
The FDA has granted Orphan Drug and Fast Track designations to eprenetapopt for treating MDS as well as acute myeloid leukemia (“AML”). The European Commission has also granted Orphan Drug designation to eprenetapopt for MDS and AML.
Zacks Rank
Aprea Therapeutics currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.